Insulin and insulin analogs: Pharmacokinetics and treatment regimens;Insulines et analogues de l'insuline: Pharmacocinetique et schemas therapeutiques

Annales de Pediatrie

Volumn 45, Issue 8, 1998, Pages 549-561

  Robert, J J ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Insulin analogs; Insulin pharmacokinetics; Insulin therapy; Insulin dependent diabetes mellitus; Intensive insulin therapy

Indexed keywords

ENDOPANCRINE ORDINAIRE; INSULATARD HM; INSULIN; INSULIN DERIVATIVE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; INSUMAN NPH; INSUMAN RAPIDE; ISOPHANE INSULIN; MONOCOMPONENT INSULIN; NEUTRAL INSULIN; RECOMBINANT HUMAN INSULIN; UMULINE NPH; UMULINE RAPIDE; UMULINE ZINC; UNCLASSIFIED DRUG;

DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG CHOICE; DRUG HALF LIFE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MOTIVATION; PATIENT COMPLIANCE; REVIEW; SELF MEDICATION; TREATMENT PLANNING;

EID: 0031684496     PISSN: 00662097     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. THE DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP. - The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med, 1993. 329, 977-986.
2. DE FRONZO R.A., TOBIN J.D., ANDRES R. - Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol, 1979, 237, E2I4-E223.
3. JENSEN I., OWENS D.R., HILDEBRANDT P., KUHL C., RIBEL U. - Comparative pharmacokinetics of commercially available insulin preparations. In: BEYER J., ALBISSER M., SCHREZENMEIR J., LEHMANN L., Computer Systems for Insulin Adjustment in Diabetes Mellitus, pp. 11-21. Hedingen. Switzerland, Panscienta-Verlag. 1985.
4. HEINE R.J., BILO H.J.G., FONK T., VAN DER VEEN E.A., VAN DER MEER J. - Action kinetics and action profiles of mixtures of short- and intermediate-acting insulins. Diahetologia, 1984, 27, 558-562.
5. LES MÉDECINS DE LA COMMISSION PÉDAGOGIQUE DE L'AJD. - Les Cahiers Je l'AJD, L'Aide aux Jeunes Diabétiques, Paris. 1993-1998,
6. DORCHY H. - Traitement du diabète de type I chez l'enfant et l'adolescent. Rev Prat, 1996, 46, 577-586.
7. HIRSCH I.B., FARKAS-HIRSCH R., SKYLER J.S. - Intensive insulin therapy for treatment of type 1 diabetes. Diabetes Care, 1990, 13, 1265-1283.
8. DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP. - Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescent with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr, 1994, 125, 177-188.
9. HOME PD. - Intensive insulin therapy in clinical practice. Diahelologia. 1997, 40, S83-S87.
10. MORTENSEN H.B., HOUGAARD P, for the Hvidore Study Group on Childhood Diabetes. - Comparison of metabolic control in a cross-sectional study of 2873 children and adolescents with IDDM from 18 countries. Diabetes Care, 1997, 20, 714-720.
11. DORCHY H., ROGGEMANS M.P., WILLEMS D. - Glycated hemoglobin and related factors in diabetic children and adolescents under 18 years of age: a Belgian experience. Diabetes Care, 1997, 20, 2-6.
12. DELAHANTY L.M., HALFORD B.N. - The role of diet behaviors in achieving improved glycemic control in intensively treated patients in the Diabetes Control and Complications Trial. Diabetes Care, 1993, 16, 1453-1458.
13. THE DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP. - Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes. 1997, 46, 271-286.
14. TUBIANA-RUFI N., MORET L., CHWALOW J., CZERNICHOW P, et le groupe collaboratif PEDIAB. - État de santé et facteurs liés au contrôle glycémique chez 165 enfants atteints de diabète insuline-dépendant âgés de 7 à 13 ans. Arch Pediatr. 1994, 1, 982-990.
15. BRANCH J., RIBEL U., HANSEN J.F., DODSON G., HANSEN M.T., HAVELUND S., MELBERG S.G., NORRIS F., NORRIS K., SNEL L., SORENSEN A.R., VOIGT H.O. - Monomeric insulins obtained by protein engineering and their medical implications. Nature, 1988, 331, 679-682.
16. KANG S., BRANGE J., BURCH A., VOLUND A., OWENS D.R. - Subcutaneous insulin absorption explained by insulin's physicochemical properties, Evidence from absorption studies of soluble human insulin and insulin analogues in humans. Diabetes Care, 1991, 14, 942-948.
17. TORLONE E., FANELLI C., RAMBOTTI A.M., KASSI G., MODARELLI F., DI VINCENZO A., EPIFANO L., CIOFETTA M., PAMPANELLI S., BRUNETTI P., BOLLI G. -Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue (Lys B28, Pro B29) in IDDM. Diabetologia. 1994, 37, 713-720.
18. HOWEY D.C., BOWSHER R.R., BRUNELLE R.L., WOODWORTH J.R. - Lys (B28), Pro (B29)-human insulin. A rapidly absorbed analogue of human insulin. Diabetes, 1994, 43, 396-402.
19. KANG S., OWENS D.R., VORA J.P., BRANGE J. - Comparison of insulin analogue B9AspB27Glu and soluble human insulin in insulin-treated diabetes. Lancet, 1990, 335, 303-306.
20. KANG S., CREAGH F.M., PETERS J.R., BRANGE J., VOLUND A., OWENS D.R. - Comparison of subcutaneous soluble human insulin and insulin analogues (AspB9GluB27: AspB10; AspB28) on meal-related plasma glucose excursions in type I diabetic subjects. Diabetes Care, 1991, 14, 571-577.
21. B R insulin treatment in young subjects with type I diabetes, Diabetic Med, 1996, 13, 47-52.
22. HEINEMANN L., HEISE T., WAHL L.C., TRAUTMANN M.E., AMPUDOIA J., STARKE A.A.R., BERGER M. - Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue (Lys B28, Pro B29) human insulin, Diabetic Med, 1996, 13, 625-629.
23. TORLONE E., PAMPANELLI S., LALLI C., DEL SINDACO P., DI VINCENZO A., RAMBOTTI A.M., MODARELLI F., EPIFANO L., KASSI G., PERRIELLO G., BRUNETTI P., BOLLI G. - Effects of the short-acting insulin analog (Lys B28, Pro B29) on postprandial blood glucose control in IDDM. Diabetes Care, 1996, 19, 945-952.
24. ANDERSON J.H., BRUNELLE R.C., KOIVISTO V.A., PFUTZNER A., TRAUTMANN M.H., VIGNATI L., DI MARCHI R., the Multicenter Insulin Lispro Study Group, Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes. 1997, 46, 265-270.
25. JACOBS M.A.J.M., KEULEN E.T.P., KANC K., CASTELEIJN S., SCHEFFER P., DEVILLÉ W., HEINE R.J. Metabolic efficacy of prcprandial administration of Lys (B28), Pro (B29) human insulin analog in IDDM patients. Diabetes Care, 1997, 20, 1279-1286.
26. HOLLEMAN F., SCHMITT H., ROTTIERS R., REES A., SYMANOWSKI S., the Benelux-UK Insulin Lispro Study Group. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin Lispro. Diabetes Care, 1997, 20, 1827-1832.
27. PFÜTZNER A., KÜSTNER E., FORST T., SCHULZESCHLEPPINGHOFF B., TRAUTMANN M.E., HASLBECK M., SCHATZ H., BEYER J., the German Insulin Lispro/IDDM study group. - Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes. Exp Clin Endocrinol Diabetes, 1996, 104, 25-30.
28. BASTYR E.J., HOLCOMBE J.H., ANDERSON J.H., CLORE J.N. Mixing insulin Lispro and Ultralente insulin. Diabetes Care, 1997, 20, 1047-1048.
29. BURGE M.R., WATERS D.L., HOLCOMBE J.H., SCHADE D.S. - Prolonged efficacy of short acting insulin Lispro in combination with human Ultralente in insulin-dependent Diabetes Mellitus. J Clin Endocrinol Metab, 1997, 82, 920-924.
30. KOSTANOS J.G., VIGNATI L., HUSTER W., ANDREJASICH C., BOGGIS M.B., JACOBSON A.M., MARRERO D., MATHIAS S.D., PATRICK D., ZALANI S., ANDERSON J. Health-related quality-of-life results from multinational clinical trials of insulin Lispro. Assessing benefits of a new diabetes therapy. Diabetes Care, 1997, 20, 948-958.
31. TUBIANA-RUFI N., MUNZ-LICHA G. - Analogue Lispro et vie quotidienne. Diabetes Metab. 1997, 23, 58-62.
32. BERGER M., HEINEMANN L. - Are presently available insulin analogues clinically beneficial? Diabetologia, 1997, 40, S91-S96.
33. ZINMAN B., TILDESLEY H., CHIASSON J.L., TSUI E., STRACK T. - Insulin Lispro in CSII. Results of a double-blind crossover study. Diabetes, 1997, 46, 440-443
34. EBELING P., JANSSON P.A., SMITH U., LALLI C., BOLLI G.B., KOIVISTO V.A. - Strategies toward improved control during insulin Lispro therapy in IDDM. Importance of basal insulin. Diabetes Can: 1997, 20, 1287-1289.
35. JORGENSEN S., VAAG A., LANGKJAER L. et al. - Novosol basal: pharmacokinetics of a novel soluble long acting insulin analogue, Br Med J, 1989, 299, 415-419.
36. HILSTED J., MADSBAD S., HVIDBERG A., RASMUSSEN M.H., KRARUP T.. IPSEN H., HANSEN B., PEDERSEN M., DJURUP R., OXENBOLL B. - Intranasal insulin therapy: the clinical realities, Diabetologia, 1995, 38, 680-684.
37. DAMGÉ C., MICHEL C., APRAHAMIAN M., COUVREUR P. -New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes, 1988, 37, 246-251.
38. MURLIN J.R., GIBBS C.B.F., ROMANOSKY M.J., STEINHAUSEN T.B., TRAUX F.L. - Effectiveness of per-oral insulin in human diabetes. J Clin Invest, 1940, 19, 703-722.
39. JAREMKO J., RORSTAD O. - Advances toward the implantable artificial pancreas for treatment of diabetes. Diabetes Care, 1998, 21, 444-450.